Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

Authors: Karolin Behringer, Helen Goergen, Felicitas Hitz, Josée M. Zijlstra, Richard Greil, Jana Marková, Stephanie Sasse, Michael Fuchs, Max S. Topp, Martin Soekler, Stephan Mathas, Julia Meißner, Martin Wilhelm, P. Koch, Hans‐Walter Lindemann, Enrico Schalk, R. Semrau, Jan Kříž, Tom Vieler, Martin Bentz, Elisabeth Lange, Rolf Mahlberg, Andre Hassler, Martin Vogelhuber, D Hahn, J. Mezger, Stefan W. Krause, Nicole Skoetz, Boris Böll, Bastian von Tresckow, Volker Diehl, Michael Hallek, Peter Borchmann, Harald Stein, Hans Theodor Eich, Andreas Engert - The Lancet 2014 cited by 181